{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "priceHint": 2, "regularMarketChange": 2.2200012, "currency": "USD", "regularMarketTime": 1684171798, "regularMarketDayHigh": 43.835, "regularMarketDayRange": "41.39 - 43.835", "regularMarketDayLow": 41.39, "regularMarketVolume": 267343, "regularMarketPreviousClose": 41.6, "bid": 43.47, "ask": 43.55, "bidSize": 11, "askSize": 8, "fullExchangeName": "NasdaqGS", "firstTradeDateMilliseconds": 1643985000000, "financialCurrency": "USD", "regularMarketOpen": 41.68, "averageDailyVolume3Month": 523950, "averageDailyVolume10Day": 555200, "fiftyTwoWeekLowChange": 37.785, "fiftyTwoWeekLowChangePercent": 6.2609777, "fiftyTwoWeekRange": "6.035 - 48.915", "fiftyTwoWeekHighChange": -5.095001, "fiftyTwoWeekHighChangePercent": -0.1041603, "fiftyTwoWeekLow": 6.035, "fiftyTwoWeekHigh": 48.915, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "marketState": "REGULAR", "regularMarketChangePercent": 5.3365417, "regularMarketPrice": 43.82, "exchange": "NMS", "shortName": "Arcellx, Inc.", "longName": "Arcellx, Inc.", "messageBoardId": "finmb_312283010", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -4.61, "epsForward": -3.19, "epsCurrentYear": -1.98, "priceEpsCurrentYear": -22.131313, "sharesOutstanding": 47993500, "bookValue": 4.647, "fiftyDayAverage": 33.9269, "fiftyDayAverageChange": 9.893101, "fiftyDayAverageChangePercent": 0.2916005, "twoHundredDayAverage": 26.440825, "twoHundredDayAverageChange": 17.379175, "twoHundredDayAverageChangePercent": 0.6572857, "marketCap": 2370762752, "forwardPE": -13.736677, "priceToBook": 9.42974, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-02-04", "averageAnalystRating": "1.3 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Arcellx", "symbol": "ACLX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "25 West Watkins Mill Road", "address2": "Suite A", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 327 0630", "website": "https://arcellx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 98, "companyOfficers": [{"maxAge": 1, "name": "Mr. Rami  Elghandour", "age": 43, "title": "Chairman, CEO & Pres", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 1024738, "fmt": "1.02M", "longFmt": "1,024,738"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 49765452, "fmt": "49.77M", "longFmt": "49,765,452"}}, {"maxAge": 1, "name": "Ms. Michelle Lim Gilson", "age": 29, "title": "Chief Financial Officer", "yearBorn": 1993, "fiscalYear": 2022, "totalPay": {"raw": 832801, "fmt": "832.8k", "longFmt": "832,801"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christopher R. Heery M.D.", "age": 42, "title": "Chief Medical Officer", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 688550, "fmt": "688.55k", "longFmt": "688,550"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2507643, "fmt": "2.51M", "longFmt": "2,507,643"}}, {"maxAge": 1, "name": "Mr. Michael  Dombeck M.B.A.", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Narinderjeet  Singh M.S.", "age": 50, "title": "Chief Technical Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Tice Ph.D.", "age": 51, "title": "Chief Scientific Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Myesha  Lacy", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Maryam  Abdul-Kareem J.D., M.S.", "title": "Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kate  Aiken", "title": "Chief People Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Neeraj P. Teotia", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}